IL3RA and acute myeloid leukemia: Other groups are also trying to develop CAR-NK therapies for the treatment of AML, targeting highly expressed antigens on AML blasts as CD123 (Morgan et al., 2021; Caruso et al., 2022) or CD70 (Choi et al., 2021).